Outcomes
| Clinical outcomes . | Median (range) or N (%) . |
|---|---|
| Best response to CAR-T | |
| CR | 56 |
| PR/VGPR | 24 |
| SD | 5 |
| PD | 14 |
| Not assessed | 1 |
| CRS | 76 |
| CRS grade | |
| 1 | 50 |
| 2 | 25 |
| 3 | 0 |
| 4 | 1 |
| 5 | 0 |
| ICANS | 33 |
| ICANS grade | |
| 1 | 14 |
| 2 | 9 |
| 3 | 7 |
| 4 | 0 |
| 5 | 3 |
| Received corticosteroids for CRS and/or ICANS | 40 |
| Follow-up time from CAR-T infusion, median (range), mo | 14 (0.4-36) |
| Alive at the time of data cutoff | 62 |
| Index CAR-T hospitalization length of stay, median (range), d | 14.5 (4-47) |
| Hospital readmission within 6 mo of CAR-T infusion | 41 |
| ICU admission within 6 mo of CAR-T infusion | 9 |
| Overall survival, median (range), mo | NR (95% CI, 20.3-NR) |
| Clinical outcomes . | Median (range) or N (%) . |
|---|---|
| Best response to CAR-T | |
| CR | 56 |
| PR/VGPR | 24 |
| SD | 5 |
| PD | 14 |
| Not assessed | 1 |
| CRS | 76 |
| CRS grade | |
| 1 | 50 |
| 2 | 25 |
| 3 | 0 |
| 4 | 1 |
| 5 | 0 |
| ICANS | 33 |
| ICANS grade | |
| 1 | 14 |
| 2 | 9 |
| 3 | 7 |
| 4 | 0 |
| 5 | 3 |
| Received corticosteroids for CRS and/or ICANS | 40 |
| Follow-up time from CAR-T infusion, median (range), mo | 14 (0.4-36) |
| Alive at the time of data cutoff | 62 |
| Index CAR-T hospitalization length of stay, median (range), d | 14.5 (4-47) |
| Hospital readmission within 6 mo of CAR-T infusion | 41 |
| ICU admission within 6 mo of CAR-T infusion | 9 |
| Overall survival, median (range), mo | NR (95% CI, 20.3-NR) |
CR, complete response; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.